Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$152.64 USD

152.64
7,027,769

-2.40 (-1.55%)

Updated Nov 12, 2024 04:00 PM ET

After-Market: $152.80 +0.16 (0.10%) 7:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks News

Panel Of Zacks Experts headshot

Top Stock Picks for the Week of October 29th

Our experts take a look at two good defensive plays.

What's in the Cards for Geron (GERN) This Earnings Season?

In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.

Mark Vickery headshot

Top Analyst Reports for Johnson & Johnson, UnitedHealth, AT&T & Intel

Today's Research Daily features new research reports on 17 major stocks, including Johnson & Johnson (JNJ), UnitedHealth (UNH), AT&T (T) and Intel (INTC).

Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO

Merck (MRK) and Bristol-Myers (BMY) report mixed third-quarter results. Pharma bigwigs present cancer data at ESMO.

J&J Intends to Buy Residual Stake in Japanese Skincare Firm

Johnson & Johnson (JNJ) makes a tender offer to buy the leftover stake in Japanese skincare firm Ci:z Holdings for about $2.05 billion in cash to strengthen its dermatology portfolio.

Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG

Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.

Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC

The FDA defers decision by three months regarding the sBLA of Bristol-Myers' (BMY) Opdivo in combination with Yervoy for the treatment of metastatic first-line NSCLC.

Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines

Biogen beat estimates for both earnings and sales in the third quarter. Its newest drug Spinraza performs well in the quarter.

Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT

Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.

Johnson & Johnson (JNJ) Stock Moves -0.27%: What You Should Know

In the latest trading session, Johnson & Johnson (JNJ) closed at $138.68, marking a -0.27% move from the previous day.

BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?

We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.

The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet

The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet

David Borun headshot

Quiet Friday Session Caps Another Volatile Week in the Markets

Earnings and Geopolitical events contribute to another wild ride

Ryan McQueeney headshot

Upcoming Tech Earnings to Watch: MSFT, AMZN, GOOGL

More major tech reports will begin pouring in next week, and Wall Street will be hoping for strength from the sector's leaders. Here's a close look at a few of the major tech earnings reports due out in the coming days.

Ryan McQueeney headshot

Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch

Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.

Neena Mishra headshot

Top-Ranked Healthcare ETFs for Long-Term Investors

Healthcare is now the best-performing sector of 2018. We highlight two top-ranked ETFs suitable for long-term investors.

Stock Market News For Oct 17, 2018

Wall Street rebounded on Tuesday as stocks surged across the board due to strong third-quarter 2018 earnings results and impressive economic data.

Tracey Ryniec headshot

This Week's Most Spectacular Earnings Charts

It doesn't get much better than these five big cap companies with their outstanding earnings surprise records and great earnings charts.

Ryan McQueeney headshot

Will Tuesday's Earnings Reports Inspire a Stock Market Rebound?

Ryan McQueeney recaps the morning's top pre-market earnings reports from Goldman Sachs, Morgan Stanley, and Johnson & Johnson. Later, he is joined by Zacks Strategist Dave Bartosiak to discuss upcoming reports from Netflix and IBM.

Q3 Earnings Reports: MSFT, NFLX, GS, MS, UNH, JNJ

Q3 Earnings Reports: MSFT, NFLX, GS, MS, UNH, JNJ

Mark Vickery headshot

Q3 Earnings Results Impress: GS, MS, UNH & More

Q3 earnings reports are hitting the tape fast and furious at this hour. We will take this opportunity to summarize a handful of them.

J&J (JNJ) Beats Earnings & Sales Estimates in Q3, Ups View

J&J (JNJ) beats estimates for both earnings and sales in the third quarter of 2018 and raises full-year forecast.

Johnson & Johnson (JNJ) Surpasses Q3 Earnings and Revenue Estimates

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 0.99% and 2.19%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

JPMorgan, Wells Fargo, Citigroup, Johnson & Johnson, Netflix and Schlumberger are part of Zacks Earnings Preview

JPMorgan, Wells Fargo, Citigroup, Johnson & Johnson, Netflix and Schlumberger are part of Zacks Earnings Preview

David Borun headshot

Friday Bounce Ends a Volatile Week for Stocks

Interest rates fears fuel the biggest weekly decline in 7 months